Search
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigational[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in
Rescinnamine
go.drugbank.com/drugs/DB01180ApprovedRescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from _Rauwolfia serpentina_ and other species of _Rauwolfia_.
Categories: Agents Acting on the Renin-Angiotensin SystemFerric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency. … [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBetula pendula tar oil
go.drugbank.com/drugs/DB11361ApprovedNutraceuticalBetula pendula tar oil is an essential oil found in the buds of the plant with the same name. … [T219] The utilization of this product started during the second world war in the Sovietic Union.
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigationalPatients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body. … Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder.
Procaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215]. … A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
Products: SATYA®AL 1%, PROCAINA AL 1%Trolamine
go.drugbank.com/drugs/DB13747ApprovedInvestigationalIt is commonly used as a pH adjuster and surfactant in industrial and cosmetic products such as skin and hair conditioning products. … Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174].